Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
Tobias Tichelbäcker/LinkedIn
Sep 1, 2026, 18:03

Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound

Tobias Tichelbäcker, Specialist in Internal Medicine and Cardiology at Fachinternistische Versorgung Rodenkirchen and University Hospital Cologne, shared a post on LinkedIn:

“PRAGUE-26 – presented at European Society of Cardiology Meeting 2026 today and published in NEJM. Congratulations to Josef Kroupa, Viktor Kočka and the Charles University Prague team!

The design

  • Investigator-initiated, non-industry, 11 centers, 558 pts with intermediate-high-risk PE.
  • 1:1: conventional catheter-directed lysis with anticoagulation vs. anticoagulation alone.
  • Lysis: 1 mg/h per catheter, approximately 20 mg alteplase over about 9 h — and no ultrasound.

The result

Primary endpoint (death, PE recurrence, cardiorespiratory decompensation or collapse 7d): 0.7% vs. 6.8% · RR 0.10 · p less than 0.001, driven mainly by fewer decompensation events

Bleeding comparable (4.6% vs. 5.0%). 2 intracranial hemorrhages, both in the lysis arm — but both explained: one during a hypertensive episode post-infusion, one with an LMWH overdose. Not a diffuse lytic signal, but a reminder that BP control and anticoagulation management matter.

PRAGUE-26 vs. HI-PEITHO

Parallels: both RCTs vs. anticoagulation, both positive, effect carried by prevented decompensation, no bleeding signal

Differences:

  • Ultrasound-CDT (EkoSonic) vs. simple CDT
  • Industry- vs. academically funded
  • HI-PEITHO more strictly selected (approximately 87% screened, not randomized), resulting in sicker cohort; PRAGUE-26 broader (control event rate 6.8% vs. 10.3%)
  • And notably: PRAGUE-26 used a slightly higher lytic dose over a longer infusion (approximately 20 mg /  approximately 9 h vs. approximately 17 mg / approximately 7 h) — without ultrasound

The elephant in the room: do we even need the ultrasound? Both show catheter lysis beats anticoagulation — but neither compares US-CDT head-to-head with simple CDT. PRAGUE-26 suggests a large benefit without ultrasound: cheaper, more widely available.

Caveat: it’s a cross-trial inference, not a direct comparison.

For intermediate-high-risk PE, ‘anticoagulate and watch’ is under pressure. The next ESC guideline will be worth reading.”

Stay updated with Hemostasis Today.

Anticoagulation Blood CDT Charles University Prague ESC Congress 2026 European Society of Cardiology Health Hematology Hemostasis Hemostasis News Hemostasis Today Josef Kroupa Medicine NEJM PE RCTs Tobias Tichelbäcker Ultrasound-CDT Viktor Kočka
NewsFeed